BR112016028918A2 - tratamento de hipertrigliceridemia grave - Google Patents

tratamento de hipertrigliceridemia grave

Info

Publication number
BR112016028918A2
BR112016028918A2 BR112016028918A BR112016028918A BR112016028918A2 BR 112016028918 A2 BR112016028918 A2 BR 112016028918A2 BR 112016028918 A BR112016028918 A BR 112016028918A BR 112016028918 A BR112016028918 A BR 112016028918A BR 112016028918 A2 BR112016028918 A2 BR 112016028918A2
Authority
BR
Brazil
Prior art keywords
treatment
severe hypertriglyceridemia
mbx
type
hypertriglyceridemia
Prior art date
Application number
BR112016028918A
Other languages
English (en)
Inventor
A Mcwherter Charles
Boudes Pol
L Martin Robert
Choi Yun-Jung
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of BR112016028918A2 publication Critical patent/BR112016028918A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção refere-se ao tratamento de hipertrigliceridemia grave, tal como hiperlipoproteinemia tipo i ou tipo v, por meio de terapia com mbx-8025 ou um sal de mbx-8025, isolado ou em combinação com um ou mais de: fibrato, niacina e ácido graxo ômega 3, opcionalmente, acompanhado por aférese.
BR112016028918A 2014-06-26 2015-06-25 tratamento de hipertrigliceridemia grave BR112016028918A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
BR112016028918A2 true BR112016028918A2 (pt) 2017-08-22

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028918A BR112016028918A2 (pt) 2014-06-26 2015-06-25 tratamento de hipertrigliceridemia grave

Country Status (16)

Country Link
US (1) US20150374649A1 (pt)
EP (1) EP3160458A1 (pt)
JP (1) JP2017519028A (pt)
KR (1) KR20170020514A (pt)
CN (1) CN106470675A (pt)
AU (1) AU2015279905A1 (pt)
BR (1) BR112016028918A2 (pt)
CA (1) CA2951280A1 (pt)
CL (1) CL2016003290A1 (pt)
EA (1) EA201790091A1 (pt)
HK (1) HK1231380A1 (pt)
IL (1) IL249757A0 (pt)
MX (1) MX2016017081A (pt)
PH (1) PH12016502415A1 (pt)
SG (1) SG11201610243YA (pt)
WO (1) WO2015200580A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102000332B1 (ko) 2014-03-20 2019-07-15 사이머베이 쎄라퓨틱스, 인코퍼레이티드 간내 담즙정체성 질환의 치료
MX369921B (es) 2014-04-11 2019-11-26 Cymabay Therapeutics Inc Tratamiento de la hgna y ehna.
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004022179D1 (de) 2003-09-19 2009-09-03 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
MA34097B1 (fr) * 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1

Also Published As

Publication number Publication date
KR20170020514A (ko) 2017-02-22
HK1231380A1 (zh) 2017-12-22
SG11201610243YA (en) 2017-01-27
WO2015200580A1 (en) 2015-12-30
CL2016003290A1 (es) 2017-09-08
JP2017519028A (ja) 2017-07-13
AU2015279905A1 (en) 2017-02-02
CN106470675A (zh) 2017-03-01
EA201790091A1 (ru) 2017-07-31
PH12016502415A1 (en) 2017-02-27
IL249757A0 (en) 2017-02-28
EP3160458A1 (en) 2017-05-03
CA2951280A1 (en) 2015-12-30
MX2016017081A (es) 2017-05-01
US20150374649A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
BR112016028918A2 (pt) tratamento de hipertrigliceridemia grave
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
NZ732799A (en) Picolinamides with fungicidal activity
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
PH12016502167A1 (en) Hdl theraphy markers
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
MX2017005457A (es) Metodos y compuestos agonistas de gip.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
PH12016502311A1 (en) Omega-3 analogues
BR112017014552A2 (pt) ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?
ZA201703214B (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX366805B (es) Uso de sulfato de zinc coceth como un agente antibacteriano en contra de propionibacterium acnes.
BR112018008181A2 (pt) baclofen intravenoso e métodos de tratamento
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
Fattahi Ardakani Reviewing the Explanations of the Unity of All Being Principle According to Ayatollah Javadi Amolie
SYUKUR THE USE OF REALITA TO IMPROVE STUDENTS'SPEAKING ABILITY THROUGH PROCEDURE TEXT AT SMPN 23 MAKASSAR
UA95472U (uk) Спосіб лікування хворих на неалкогольну жирову хворобу печінки
UA28502S (uk) Катетер для ін'єкцій типу метелик
EA201991189A1 (ru) СТИМУЛЯТОРЫ sGC

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements